Background The majority of prolactinomas respond to dopamine agonist therapy, but a
proportion are resistant, requiring other treatments including surgery and/or radiotherapy …

Prolactinomas are common tumors of the anterior pituitary gland. While conventional
therapies, including dopamine agonists, transsphenoidal surgery and radiotherapy, are …

Abstract Pituitary tumors represent 10–15% of all intracranial tumors; of these, prolactinomas
account for 40–50% of cases. Prolactinomas usually respond well to dopamine agonists …

Interventions: The patient received the most frequently recommended regimen of
temozolomide treatment for 22 cycles. Outcomes: Temozolomide resulted in a remarkable …

Therapeutic agents for refractory prolactinomas that are resistant to dopamine agonists
(DAs) are troublesome, and surgery often only removes a large part of the tumor without …

Prolactinomas are the most common functional pituitary tumors, accounting for 40% of all
pituitary adenomas. Medical treatment with dopamine agonists (DA), mainly cabergoline, is …

Purpose Aggressive prolactinomas are defined as radiologically invasive tumors which
cannot be cured by surgery, and that have an unusually rapid rate of tumor growth despite …

BACKGROUND AND IMPORTANCE: The case presented here describes the clinical
evolution of a pituitary carcinoma from an atypical prolactinoma after temozolomide (TMZ) …

Administration of temozolomide to a 46-year-old man with an invasive aggressive prolactin
(PRL)–secreting pituitary neoplasm resulted in improvement of the clinical condition and …

Purpose Refractory prolactinomas resistant to dopamine agonists (DAs) pose a clinical
challenge. Temozolomide (TMZ) is a recommended treatment option, but its effects are …